Trial NCT01076556

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2011-01373
Secondary IDs: 8267 CDR0000666448 NCI-2011-01373 OSU 09089 OSU-09089 P30CA016058 U01CA076576

Last trial update was posted on 2015-11-11

MeSH Interventions

Alvocidib Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Cyclophosphamide Immunoglobulins Rituximab

MeSH Conditions

Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Leukemia, Prolymphocytic Lymphoma

Other Conditions

Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage I Small Lymphocytic Lymphoma Stage II Chronic Lymphocytic Leukemia Stage II Small Lymphocytic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Small Lymphocytic Lymphoma

Stopping Reasons

N/A

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID